Tridentate platinum, palladium, and gold complexes of Formulas A-I and A-II and tridentate iridium and rhodium compounds of Formulas B-I, B-II, and B-III suitable for delayed fluorescent and phosphorescent or phosphorescent emitters in display and lighting applications. ##STR00001## ##STR00002##

A heterocyclic compound and an organic light-emitting device including the same are provided. The organic light-emitting device includes: a first electrode; a second electrode facing the first electrode; and an organic layer disposed between the first electrode and the second electrode, where the organic layer may include an emission layer and at least one of the heterocyclic compound described above.

An organic electroluminescence device and a polycyclic compound used for the organic electroluminescence device are provided. The polycyclic compound according to an embodiment of the inventive concept is represented by Formula 1. In Formula 1, Y is B, P═O, or P═S, and X is SiR.sub.3R.sub.4, or GeR.sub.5R.sub.6. At least one of R.sub.1 or R.sub.2 is NAr.sub.2Ar.sub.3. ##STR00001##

The invention relates to oligomerization of olefins, such as ethylene, to higher olefins, such as a mixture of 1-hexene and 1-octene, using a catalyst system that comprises a) a source of chromium b) one or more activators and c) a phosphacycle-containing ligating compound. Additionally, the invention relates to a phosphacycle-containing ligating compound and a process for making said compound.

The present disclosure relates to a compound, an organic electroluminescent device, and a display device. The compound has a structure of formula (I) ##STR00001## X is selected from a C atom, a Si atom, a B atom, or a P atom; Y.sub.1 to Y.sub.4 are each independently selected from a C atom or an N atom; A and B are each independently selected from any one or more of a substituted or unsubstituted C6-C40 aryl group and a substituted or unsubstituted C4-C40 heteroaryl group; R.sub.1 is selected from carbonyl, C1-C9 alkyl, a substituted or unsubstituted C6-C18 aryl group, and a substituted or unsubstituted C4-C30 heteroaryl group; and R.sub.2 and R.sub.3 are each independently selected from any one of a C1-C9 alkyl group, a substituted or unsubstituted C6-C18 aryl group, and a substituted or unsubstituted C4-C30 heteroaryl group, and n is selected from 0 or 1.

An organic compound, an electroluminescent material and its application are provided in the present disclosure. The organic compound includes a structure:

##STR00001##

X is selected from O, S, N—R.sub.N1, and CR.sub.C1R.sub.C2; Y is selected from O, S, N—R.sub.N2, CR.sub.C3R.sub.C4, O═S═O, SiR.sub.S1R.sub.S2, O═P—Ar.sub.1, and S═P—Ar.sub.2, R.sub.N1, R.sub.N2, R.sub.C1, R.sub.C2, R.sub.C3, R.sub.C4, R.sub.S1, and R.sub.S2 are each independently selected from C1˜C20 linear or branched alkyl, C6˜C40 aryl, and C3˜C40 heteroaryl; Ar.sub.1 and Ar.sub.2 are each independently selected from C6˜C40 aryl and C3˜C40 heteroaryl; L.sub.1, L.sub.2, L.sub.3, L.sub.4, and L.sub.5 are each independently selected from a single bond, C6˜C40 arylene, and C3˜C40 heteroarylene; R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are each independently selected from deuterium, C1˜C20 linear or branched alkyl, C1˜C20 alkoxy, C1˜C20 alkylthio, C3˜C20 cycloalkyl, C6˜C40 aryl, C3˜C40 heteroaryl, and C6˜C40 arylamino; and n.sub.1, n.sub.2, n.sub.3, n.sub.4, n.sub.5, m.sub.1, m.sub.2, m.sub.3, m.sub.4, and m.sub.5 are integers each independently selected from 0-2.

The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.

Provided herein are inhibitors of MEK kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MEK kinase inhibitory compounds for the treatment of disease.

A compound useful as a CDK7 kinase inhibitor has a structure shown in formula I The definition of each group and substituent is as described in the description. The compound invention can be used as an inhibitor of cyclin-dependent kinase 7 (CDK7) for the treatment or prevention of proliferative diseases (such as cancers), and in particular for the regulation and treatment of related diseases caused by abnormal activity of cyclin-dependent kinase 7 (CDK7).

##STR00001##

A compound having a structure shown in Chemical Formula 1 is described. In an embodiment, Ar is C6-C20 aryl or C5-C20 heteroaryl; D.sub.1 and D.sub.2 are electron-donating groups, A.sub.1 and A.sub.2 are electron-accepting groups, and m, n, p and q are 1, 2, or 3; D.sub.1 and D.sub.2 are a substituted or unsubstituted C1-C20 alkyl, a substituted or unsubstituted C3-C20 cycloalkyl, a substituted or unsubstituted C1-C20 alkoxy, a substituted or unsubstituted C3-C20 heterocyclic group, a substituted or unsubstituted C6-C40 aryl, a substituted or unsubstituted C4-C40 heteroaryl, a substituted or unsubstituted C10-C60 fused aryl, a substituted or unsubstituted C10-C60 fused heteroaryl, a substituted or unsubstituted C12-C40 carbazolyl, a substituted or unsubstituted C12-C40 diphenylamino group, or a C13-C40 acridinyl; and A.sub.1 and A.sub.2 are each a nitrogen-containing heterocyclic group, a cyano-containing group, a carbonyl-containing group, a sulfone-based group, and a phosphoroso-containing group. ##STR00001##